FFPE-based RAD51 assays have previously been described in breast cancer samples (26–28), epithelial ovarian cancer (30) and ovarian/endometrial cancer sample cohorts (29), but never for advanced HGSC specifically. This evidence concerns the gene RAD51 and breast cancer.